Product List

Symphony™ Cardiac Assist Device

Atrial Fibrillation Device

Stroke Prevention Device

Sports Medicine


Paul Spence, MD

Abiomed® Symphony™ Cardiac Assist Device

Congestive heart failure is one of the largest unsolved problems in cardiac care today affecting more than five million patients in the United States alone. Despite advances in medical therapy many patients eventually deteriorate to the point where they require mechanical circulatory support. Unfortunately, despite many years of research and millions of dollars of expenditure, only about 3,000 patients receive mechanical circulatory support each year.

Most current mechanical circulatory support devices require a major surgical procedure (sternotomy) and the use of cardiopulmonary bypass for implantation. Further, postoperative management of these patients can be challenging and costly.

Despite the fact that the intra aortic balloon pump (IABP) has been successfully used for more than 20 years for the short-term treatment of cardiac dysfunction, there is no long-term counterpulsation therapy currently available. With more than 150,000 IABP implanted every year, it is the most widely used mechanical cardiac support device available.

However, the IABP insertion methodology, location at the descending thoracic aorta, and the biocompatibility of the IABP catheter limits its application to short durations.

The SCR-developed Symphony™ offers the traditional benefits of IABP in a device that can be used over the long term to treat heart failure patients who may be responsive to a milder form of cardiac assistance.

The Symphony™ is designed for superficial implantation without the need to enter the chest, enabling complete patient mobility. The device is a valveless pneumatically driven blood sac that fits ergonomically in a "pacemaker pocket" with the conduit connected to the subclavian artery. It is operated by a small, wearable pneumatic driver connected to the sac by a percutaneous air line and timed to the patient's ECG.

The device fills during the heart's natural expansion, lowering the muscle's workload. It ejects during the heart's natural contraction, increasing blood flow throughout the body, thereby improving the patient's overall health.

For more information, view a slide show or contact SCR

Atrial Fibrillation Device

Atrial Fibrillation is a cardiovascular epidemic. AF is a commonly encountered clinical arrhythmia, especially in the elderly and in those with co-existing cardiac disease. AF can be associated with several serious complications such as left atrial thrombus, cardioembolism and stroke, heart failure (including tachycardia-induced cardiomyopathy), and hemodynamic impairment. Clearly, AF is not a benign disease.

As AF increases cardiovascular morbidity and mortality, it follows that restoring and maintaining normal sinus rhythm in such patients would improve prognosis. In view of the difficulties in achieving rhythm control through medical therapies, catheter ablation for AF offers a promising nonpharmacological approach for curing AF. Indeed, several studies have demonstrated that catheter ablation is more effective in maintaining sinus rhythm and improves morbidity and mortality compared with antiarrhythmic drugs. Moreover, AF ablation in patients with heart failure improves left ventricular function.

SCR, Inc., in conjunction with the Cardiovascular Innovation Institute and the University of Louisville’s Speed School of Engineering, is developing a low-cost catheter guidance system that can be used with clinically-available RF ablation catheters to provide rapid ablation to produce lesions that have the highest success in restoring and maintaining sinus rhythm.

For more information, contact SCR

Stroke Prevention Device

Two and a half million people have atrial fibrillation in the United States. Patients with atrial fibrillation are at a significantly elevated risk for embolic stroke. Embolic strokes are caused by blood clots that originate in the left atrium and travel to the brain through the aortic arch vessels.

Anticoagulation with warfarin is the current treatment of choice for these patients. However 40%-65% of elderly patients who are at high risk of stroke are not placed on anticoagulation with warfarin due to the elevated risk of bleeding.

To address this clinical need, SCR Inc. is developing a simple implantable device to prevent embolic strokes.

For more information, contact SCR.

Sports Medicine

Premier athletes and recreational athletes frequently experience serious muscle injury that can impair performance and enjoyment of recreation.

SCR is developing a line of products to prevent injury and promote muscular recovery following vigorous athletic activity.

For more information, contact SCR.